Wnt modulators, sustained-release TKIs, and topical steroids are in phase 3 trials for DME, offering alternatives to anti-VEGF injections.
Matt Hoffman
Advertisement
Matt Hoffman is the editorial director for the Eye Care Network (Ophthalmology Times, Modern Retina, Ophthalmology Times Europe, and Optometry Times) as well as NeurologyLive, Contagion, IJMSC, and CGTLive. He has covered medical news for MJH Life Sciences, the parent company, since 2017.
He executive produces the Optometry Times podcast, From Paper to Clinic, and previously hosted the Medical World News shows Deep Dive and Second Opinion.
You can follow him on X @byMattHoffman and on LinkedIn, or email him at [email protected].
Articles by Matt Hoffman
Gene therapies, Tie2 agonism, and new delivery platforms are advancing through phase 3 trials in wet and dry AMD, testing mechanisms distinct from anti-VEGF and complement inhibition.
When patients fall outside pivotal clinical trial criteria, retina specialists factor in real-world judgment to guide treatment.
Advertisement
Latest Updated Articles
Advertisement
Advertisement